Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00742573 · ClinicalTrials.gov registry record · Phase 2
Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics
A Phase 2 study of Major Depressive Disorder, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
- 1
- Study location
NCT00742573 is a Phase 2 study of Major Depressive Disorder that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 170 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00742573, a Phase 2 study of Major Depressive Disorder, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine whether combination treatment driven by patient choice is better than standardized medication treatment at retaining and improving Hispanic patients with major depressive disorder.
Conditions Studied
Interventions
- DRUG Antidepressants through Texas Medication Algorithm (TMA)
- BEHAVIORAL Brief Interpersonal Psychotherapy (IPT-B)
Study Locations (1)
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2008-08 |
| Est. Completion | 2014-01-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00742573
The ClinicalTrials.gov registry entry for NCT00742573 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (55% lower). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Antidepressants through Texas Medication Algorithm (TMA) is the first listed.
NCT00742573 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00742573 about?
NCT00742573 is a clinical study titled "Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics". This study will determine whether combination treatment driven by patient choice is better than standardized medication treatment at retaining and improving Hispanic patients with major depressive disorder.
What is the current status of trial NCT00742573?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2008-08. Estimated completion is 2014-01-10.
What conditions does trial NCT00742573 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT00742573?
The interventions under investigation include: Antidepressants through Texas Medication Algorithm (TMA) (DRUG), Brief Interpersonal Psychotherapy (IPT-B) (BEHAVIORAL).
Who is sponsoring clinical trial NCT00742573?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00742573 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.